自由生活条件下血糖控制良好的1型糖尿病成人中闭环胰岛素输注与常规胰岛素泵治疗的昼夜血糖控制比较:一项开放标签随机交叉研究
这项开放标签随机交叉研究纳入HbA1c低于7·5%的1型糖尿病成人,比较昼夜混合闭环系统与常规胰岛素泵治疗各4周的效果。闭环期间血糖在目标范围(3·9-10·0 mmol/L)的时间比例较常规泵治疗提高10·5个百分点(95%CI 7·6-13·4;p<0·0001),低血糖时间比例降低,未发生严重低血糖或严重不良事件。
要点
- 闭环系统使目标血糖范围时间比例较常规泵治疗提高10·5个百分点。
- 闭环期间血糖低于3·5 mmol/L的时间比例降低65%,低于2·8 mmol/L降低76%。
- 未发生严重低血糖或其他严重不良事件,但需更大规模、更长随访研究。
核心结论
- 在HbA1c低于7·5%的1型糖尿病成人中,无监督自由生活条件下使用昼夜混合闭环胰岛素输注4周安全且耐受良好,改善血糖控制并减轻低血糖负担,但需更大规模、更长随访研究。
研究设计与样本
- 开放标签、随机、交叉研究,从Addenbrooke's医院(英国剑桥)和Medical University of Graz(奥地利格拉茨)招募年龄≥18岁、HbA1c低于7·5%的1型糖尿病成人,经2-4周导入期后按1:1随机分配至昼夜混合闭环系统或常规泵治疗4周,洗脱2-4周后交叉至另一干预4周,治疗在无监督自由生活条件下进行,主要结局为4周研究期间传感器血糖在3·9-10·0 mmol/L目标范围内的时间比例,按意向性分析,共31人招募、29人随机化,1人在第一个闭环期因对研究装置和血糖控制不满退出。
主要发现
- 闭环期间传感器血糖在目标范围(3·9-10·0 mmol/L)的时间比例为76·2%(SD 6·4),常规泵治疗为65·6%(SD 8·1),闭环较常规泵治疗提高10·5个百分点(95%CI 7·6-13·4;p<0·0001)。
- 与常规泵治疗相比,闭环输注使血糖低于3·5 mmol/L的时间比例降低65%(53-74;p<0·0001),低于2·8 mmol/L的时间比例降低76%(59-86;p<0·0001)。
- 未发生严重低血糖或其他严重不良事件。
临床怎么用
- 作者认为,在HbA1c低于7·5%的1型糖尿病成人中,无监督自由生活条件下使用昼夜混合闭环胰岛素输注4周安全且耐受良好,可改善血糖控制并减轻低血糖负担,但需更大规模、更长随访研究。
局限性
- 原文结论指出需更大规模、更长随访研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tight control of blood glucose concentration in people with type 1 diabetes predisposes to hypoglycaemia. We aimed to investigate whether day-and-night hybrid closed-loop insulin delivery can improve glucose control while alleviating the risk of hypoglycaemia in adults with HbA1c below 7·5% (58 mmol/mol). METHODS: In this open-label, randomised, crossover study, we recruited adults (aged ≥18 years) with type 1 diabetes and HbA1c below 7·5% from Addenbrooke's Hospital (Cambridge, UK) and Medical University of Graz (Graz, Austria). After a 2-4 week run-in period, participants were randomly assigned (1:1), using web-based randomly permuted blocks of four, to receive insulin via the day-and-night hybrid closed-loop system or usual pump therapy for 4 weeks, followed by a 2-4 week washout period and then the other intervention for 4 weeks. Treatment interventions were unsupervised and done under free-living conditions. During the closed-loop period, a model-predictive control algorithm directed insulin delivery, and prandial insulin delivery was calculated with a standard bolus wizard. The primary outcome was the proportion of time when sensor glucose concentration was in target range (3·9-10·0 mmol/L) over the 4 week study period. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT02727231, and is completed. FINDINGS: Between March 21 and June 24, 2016, we recruited 31 participants, of whom 29 were randomised. One participant withdrew during the first closed-loop period because of dissatisfaction with study devices and glucose control. The proportion of time when sensor glucose concentration was in target range was 10·5 percentage points higher (95% CI 7·6-13·4; p<0·0001) during closed-loop delivery compared with usual pump therapy (65·6% [SD 8·1] when participants used usual pump therapy vs 76·2% [6·4] when they used closed-loop). Compared with usual pump therapy, closed-loop delivery also reduced the proportion of time spent in hypoglycaemia: the proportion of time with glucose concentration below 3·5 mmol/L was reduced by 65% (53-74, p<0·0001) and below 2·8 mmol/L by 76% (59-86, p<0·0001). No episodes of serious hypoglycaemia or other serious adverse events occurred. INTERPRETATION: Use of day-and-night hybrid closed-loop insulin delivery under unsupervised, free-living conditions for 4 weeks in adults with type 1 diabetes and HbA1c below 7·5% is safe and well tolerated, improves glucose control, and reduces hypoglycaemia burden. Larger and longer studies are warranted. FUNDING: Swiss National Science Foundation (P1BEP3_165297), JDRF, UK National Institute for Health Research Cambridge Biomedical Research Centre, and Wellcome Strategic Award (100574/Z/12/Z).
引用
- Bally L, Thabit H, Kojzar H, et al. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol. 2017. PMID: 28094136. doi:10.1016/S2213-8587(17)30001-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。